Head-to-head comparison
Hims & Hers vs Signos
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Mass-market app-first program with nationwide polish — tirzepatide pricing disclosure lags the ranking.
$199/mo sema
Marked down on: Tirzepatide pricing inconsistently disclosed
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Desk Score
Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app.
$199/mo (6-month prepay) sema · From $199/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: Compounded GLP-1s are not FDA-approved finished products
Hims & Hers takes this head-to-head with the higher Desk Score, 79/100 (C+) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Hims & Hers
79/100
C+
Signos
62/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Hims & Hers | Signos |
|---|---|---|
| Semaglutide | $199/mo$199/mo | $199/mo6-month prepay$199/mo (6-month plan, compounded) |
| Tirzepatide | Not listed on Hims & Hers's site | From $199/molowest dose rung$199/mo (starting dose, compounded) |
| Coverage | All 50 states | Not listed on Signos's site (checked July 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | People who want a familiar consumer-brand app experience and don't need tirzepatide. | Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app. |
| Desk Score | 79/100C+ | 62/100C |
The verdict
Desk pick — Hims & HersHims & Hers takes this head-to-head with the higher Desk Score, 79/100 (C+) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.
Choose Hims & Hers if…
People who want a familiar consumer-brand app experience and don't need tirzepatide.
$199/mo sema · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Choose Signos if…
Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app.
$199/mo (6-month prepay) sema · From $199/mo (lowest dose rung) tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Hims & Hers · Signos.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Hims & Hers
- CoreAge Rx vs Signos
- Hims & Hers vs Ondra Health
- HealthRX vs Signos
- Hims & Hers vs Vaylen
- Breeze Meds vs Signos
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.